NEW YORK–(BUSINESS WIRE)–#A–Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) on behalf of Ventyx stockholders. Our investigation concerns whether Ventyx has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On November 6, 2023, STAT published an article regarding Ventyx’s decision to halt the development of an experimental drug for treating plaque psoriasis. Ventyx’s decision was made in spite of the Company’s reporting “proved safe and moderately effective in a mid-stage trial.”
On this news, the price of Ventyx shares declined by $11.36 per share, or approximately 80.62%, from $14.09 per share to close at $2.73 on November 7, 2023.
If you purchased or otherwise acquired Ventyx shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com